$62.87
0.69% yesterday
Nasdaq, Feb 04, 10:07 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$62.87
-4.20 6.26% 1M
-17.60 21.87% 6M
-2.86 4.35% YTD
-24.85 28.33% 1Y
-25.76 29.06% 3Y
-23.20 26.95% 5Y
-31.49 33.37% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.43 0.69%
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Key metrics

Market capitalization $11.98b
Enterprise Value $11.66b
P/E (TTM) P/E ratio 37.86
EV/FCF (TTM) EV/FCF 36.46
EV/Sales (TTM) EV/Sales 4.25
P/S ratio (TTM) P/S ratio 4.36
P/B ratio (TTM) P/B ratio 2.21
Revenue growth (TTM) Revenue growth 19.99%
Revenue (TTM) Revenue $2.75b
EBIT (operating result TTM) EBIT $390.76m
Free Cash Flow (TTM) Free Cash Flow $319.89m
Cash position $930.44m
EPS (TTM) EPS $1.66
P/E forward 27.85
P/S forward 4.25
EV/Sales forward 4.14
Short interest 2.32%
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

24x Buy
77%
7x Hold
23%

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
77%
Hold
23%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,747 2,747
20% 20%
100%
- Direct Costs 628 628
10% 10%
23%
2,118 2,118
23% 23%
77%
- Selling and Administrative Expenses 848 848
7% 7%
31%
- Research and Development Expense 780 780
9% 9%
28%
490 490
128% 128%
18%
- Depreciation and Amortization 100 100
2% 2%
4%
EBIT (Operating Income) EBIT 391 391
246% 246%
14%
Net Profit 322 322
119% 119%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Negative
Seeking Alpha
13 days ago
BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's day, and competition with their drug VOXZOGO. The sharp decline in share price invites a reassessment of BioMarin's current investment prospects.
Neutral
PRNewsWire
23 days ago
SAN RAFAEL, Calif. , Jan. 13, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany.
Neutral
PRNewsWire
30 days ago
SAN RAFAEL, Calif. , Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P.
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,401
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today